Vivacelle Bio, Inc.’s Post

Vivacelle Bio had a very successful clinical trial of its phospholipid nanoparticles in patients with severe septic shock who were not responding to standard of care. Vivacelle Bio company statement: The relatively unexplored region between life and death is the focus of our scientific journey and the source of our life saving discoveries. https://lnkd.in/ejD7aFtW

Vivacelle Bio had a very successful clinical trial of our phospholipid nanoparticles in patients who had severe septic shock. he study was published in the Lancet's eClinicalmedicine. The company is moving on to phase III. https://lnkd.in/ejD7aFtW

https://lnkd.in/dWZmUakc We, the VivacelleBio team proud to present our Ph 2a study results published in The Lancet. #VBI-S #SepticShock #Hypotension #MAPimprovement